BidaskClub upgraded shares of Xencor (NASDAQ:XNCR) from a sell rating to a hold rating in a research report released on Thursday morning.
A number of other research analysts also recently issued reports on the company. Zacks Investment Research restated a sell rating on shares of Xencor in a research note on Saturday, January 13th. Cantor Fitzgerald initiated coverage on Xencor in a research report on Wednesday, November 29th. They set an overweight rating and a $33.00 price target on the stock. Piper Jaffray Companies reaffirmed a buy rating and set a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. ValuEngine cut Xencor from a hold rating to a sell rating in a research report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 price target on Xencor and gave the company a buy rating in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $30.80.
Xencor (NASDAQ:XNCR) opened at $25.40 on Thursday. The stock has a market capitalization of $1,190.00, a price-to-earnings ratio of -25.15 and a beta of 1.97. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64.
Institutional investors and hedge funds have recently modified their holdings of the stock. Great West Life Assurance Co. Can lifted its holdings in Xencor by 158.9% during the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 4,005 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Xencor during the 3rd quarter worth about $201,000. UBS Asset Management Americas Inc. purchased a new stake in Xencor during the 4th quarter worth about $205,000. Landscape Capital Management L.L.C. purchased a new stake in Xencor during the 4th quarter worth about $220,000. Finally, Two Sigma Advisers LP purchased a new stake in Xencor during the 4th quarter worth about $278,000. 77.33% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “BidaskClub Upgrades Xencor (XNCR) to “Hold”” was first published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/02/19/bidaskclub-upgrades-xencor-xncr-to-hold.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.